MarketFriction

Kopran Ltd

NSE KOPRAN · BSE 524280 · Pharmaceuticals
₹282.05 +1.34%
NSE close2026-10-01
52 week range107.00 - 295.83
Market cap₹1,399 Cr.
P/E56.0
ASM short-term Price band 20% Delivery 33.3%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales152.59158.92186.08139.44151.56166.24172.36135.22117.91194.28234.02153.99
Expenses129.76135.34164.39121.28136.83146.39155.27121.09123.19176.52201.08138.18
Operating Profit22.8323.5821.6918.1614.7319.8517.0914.13-5.2817.7632.9415.81
OPM %14.96%14.84%11.66%13.02%9.72%11.94%9.92%10.45%-4.48%9.14%14.08%10.27%
Other Income0.132.439.672.631.000.173.262.560.030.070.092.05
Interest1.942.242.592.182.232.162.772.542.092.673.173.28
Depreciation2.773.273.593.873.854.003.874.264.284.424.525.77
Profit before tax18.2520.5025.1814.749.6513.8613.719.89-11.6210.7425.348.81
Tax %24.55%23.02%26.01%24.69%23.42%24.96%29.39%24.67%-14.63%13.04%25.57%23.84%
Net Profit13.7715.7918.6211.107.3810.409.687.45-9.929.3418.876.70
EPS in Rs2.863.283.862.301.532.162.011.54-2.061.943.911.39
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales296310313358360492478551615630681700
Expenses266274283312313410390499540557619639
Operating Profit303631464782875274736261
OPM %10%12%10%13%13%17%18%9%12%12%9%9%
Other Income11193-01811315402
Interest1314999656991011
Depreciation88991010111313161719
Profit before tax112523322883823668523433
Tax %0%20%10%24%26%26%25%24%25%26%25%
Net Profit112020242162612751392625
EPS in Rs2.484.604.745.554.8614.2412.665.6510.577.995.335.18
Dividend Payout %0%0%0%0%0%21%24%53%28%38%56%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth9%7%7%12%
Compounded Profit Growth8%-16%-2%-28%
Stock Price CAGR18%7%9%70%
Return on Equity11%9%8%5%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital414343434343434848484848
Reserves495781101125146202378391443470482
Borrowings86809589978866757599148153
Other Liabilities998478828592128110135153178225
Total Liabilities275264298315351370439611650743844908
Fixed Assets102101104104113111112151165182208346
CWIP1361024304336709711325
Investments000000000000
Other Assets172160187201214229284425415465522537
Total Assets275264298315351370439611650743844908
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity46291626253160-3334434267
Cash from Investing Activity-10-9-18-11-25-13-25-84-13-44-56-65
Cash from Financing Activity-37-192-15-1-18-35123-20126-21
Net Cash Flow-00-0-0-00052111-19
Free Cash Flow3518-014-61743-76-27-13-17-0
CFO/OP147%95%47%94%63%82%93%-17%90%77%76%117%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9170867588948997108126125141
Inventory Days78119122138129154121202133126153137
Days Payable1191159511890951048489103108131
Cash Conversion Cycle507411396127153106215152149170146
Working Capital Days934436070798115813913111391
ROCE %14%14%19%14%16%14%30%21%8%14%10%7%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters44.49%44.49%44.49%44.49%44.49%44.45%44.42%44.43%44.43%44.43%44.43%44.43%
FIIs0.39%0.48%0.84%0.68%1.31%0.86%1.11%0.76%0.60%0.36%0.57%0.51%
DIIs0.35%0.14%1.20%0.14%0.22%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public54.78%54.88%53.47%54.68%53.98%54.68%54.45%54.81%54.99%55.21%55.01%55.06%
No. of Shareholders53,79151,63650,85051,49257,15460,56058,65260,19462,22260,88658,63956,925

Fundamentals

Market Cap₹ 1,399 Cr.
Current Price₹ 291
Stock P/E56.0
Book Value₹ 110
ROCE6.65 %
ROE4.91 %
Dividend Yield1.03 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)12%
Compounded Profit Growth (TTM)-28%
Consolidated figures.
Valuation
Market capRs 1,362 Cr
Enterprise valueRs 1,507 Cr
P/E (TTM)54.50x
Price to book2.57x
Price to sales1.95x
EV / EBITDA23.75x
EV / EBIT33.89x
EV / sales2.15x
Price to cash flow20.40x
Earnings yield1.83%
Dividend yield1.06%
P/E, 3-year average22.23x
P/B, 3-year average1.72x
P/E, 5-year average21.69x
P/B, 5-year average1.91x
Profitability
Operating margin (excl. other income)9.09%
Operating margin (incl. other income)9.14%
EBITDA margin9.06%
Pre-tax margin4.75%
Net profit margin3.57%
Net margin, latest quarter4.35%
ROE4.91%
ROCE6.65%
ROA2.94%
ROE, 3-year average7.83%
ROCE, 3-year average10.06%
ROA, 3-year average5.04%
ROE, 5-year average9.60%
ROCE, 5-year average11.98%
ROA, 5-year average6.21%
ROIC (approx.)4.93%
Tax rate25.12%
Other income / net worth0.07%
Growth
Sales growth (latest year)8.23%
Profit growth (latest year)-33.26%
Sales CAGR, 3 years7.34%
Sales CAGR, 5 years6.74%
Profit CAGR, 3 years-1.87%
Profit CAGR, 5 years-16.02%
Sales growth QoQ-34.20%
Profit growth QoQ-64.49%
Sales growth YoY (latest quarter)13.88%
Profit growth YoY (latest quarter)-10.07%
Per share
EPS (TTM)Rs 5.18
EPS (latest year)Rs 5.33
EPS (latest quarter)Rs 1.39
EPS, 3-year averageRs 7.96
EPS, 5-year averageRs 8.44
Book value per shareRs 109.82
Sales per shareRs 145.01
Cash flow per shareRs 13.82
Free cash flow per shareRs -0.00
Dividend per share (latest year)Rs 3.00
Dividend per share, 3-year averageRs 3.00
Dividend per share, 5-year averageRs 3.00
Dividends
Dividend payout56.32%
Dividend payout, 3-year average40.76%
Dividend payout, 5-year average39.81%
Efficiency
Asset turnover0.75x
Fixed asset turnover1.97x
Inventory turnover2.99x
Inventory days122 days
Debtor days141 days
Debtors turnover2.59x
Creditor days131 days
Cash conversion cycle146 days
Working capital days91 days
Leverage
Total debtRs 153 Cr
Cash and bankRs 7 Cr
Net debtRs 145 Cr
Debt to equity0.29x
Net debt / EBITDA2.29x
Interest coverage3.97x
Current ratio (filing 2026-03-31)1.51x
Quick ratio (filing 2026-03-31)1.04x
Trade payables (filing 2026-03-31)Rs 158 Cr
Owners' fund to total sources58.38%
Debt to assets16.81%
Cash flow
Cash from Operating Activity (latest year)Rs 67 Cr
Cash from Investing Activity (latest year)Rs -65 Cr
Cash from Financing Activity (latest year)Rs -21 Cr
Net Cash Flow (latest year)Rs -19 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs 5 Cr
Cash from ops / profit, 5 years0.75x
Sales to cash flow10.21x
Statement figures
Net sales (TTM)Rs 700 Cr
Net sales (latest year)Rs 681 Cr
Sales (latest quarter)Rs 154 Cr
Operating profit excl. other income (latest year)Rs 62 Cr
Operating profit (latest quarter)Rs 16 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 63 Cr
PBDT (TTM)Rs 52 Cr
Profit before tax (TTM)Rs 33 Cr
Tax (latest year)Rs 9 Cr
Net profit (TTM)Rs 25 Cr
Net profit (latest year)Rs 26 Cr
Net profit (latest quarter)Rs 7 Cr
Depreciation (TTM)Rs 19 Cr
Depreciation (latest quarter)Rs 6 Cr
Interest (TTM)Rs 11 Cr
Cost of goods sold (latest year)Rs 490 Cr
Total expenditure (latest year)Rs 619 Cr
Total income (latest year)Rs 682 Cr
Share capitalRs 48 Cr
ReservesRs 482 Cr
Shareholders' fundsRs 530 Cr
Total assetsRs 908 Cr
Net blockRs 346 Cr
Capital work in progressRs 25 Cr
InvestmentsRs 0 Cr
ReceivablesRs 263 Cr
InventoryRs 164 Cr
Other liabilitiesRs 225 Cr
Shares outstanding (crore)4.83
Ownership
Promoter holding44.43% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 54.5 is at the 99th percentile of its own 9.4-year range (median 18.2, low 5.1, high 54.5).
P/B 2.57 is at the 64th percentile (median 2.05).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodKOPRANNifty 50Difference
1 week+4.2%-2.8% +6.9 pts
1 month+29.6%-6.8% +36.4 pts
3 months+45.9%-7.6% +53.5 pts
6 months+161.1%+0.4% +160.7 pts
1 year+55.9%-9.9% +65.8 pts
2 years-17.7%-13.6% -4.2 pts
3 years+24.4%+14.2% +10.2 pts
5 years+38.2%+27.9% +10.3 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.04%0

Red flags

F-score 6 of 8
lookOn NSE surveillance On NSE surveillance: ASM short-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹154 Cr +13.9% vs Jun 2025. Net profit ₹7 Cr -10.1%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-11Dividend - Rs 3 Per Share
2025-09-04Dividend - Rs 3 Per Share
2024-09-02Annual General Meeting/Dividend - Rs 3 Per Share
2023-09-07Annual General Meeting/Dividend - Rs 3 Per Share
2022-08-04Dividend - Rs 3 Per Share
2021-08-05 Dividend - Rs 1.50 Per Share
2020-11-05 Interim Dividend - Rs 1.50 Per Share
2020-09-03 Annual General Meeting
2019-07-08 Annual General Meeting
2018-08-27 Annual General Meeting
2017-08-29 Annual General Meeting
2016-09-06 Annual General Meeting
2015-09-15 Annual General Meeting
2014-09-04Annual General Meeting
2013-09-06Annual General Meeting
2012-09-10Annual General Meeting
2011-09-19Annual General Meeting
2010-09-20Annual General Meeting
2009-09-18Annual General Meeting
2008-09-22Annual General Meeting
2008-03-18Annual General Meeting
2006-09-22Agm
DateTypeWhat it says
2026-09-22Price movementSignificant movement in price has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information ab...
2026-09-21Price movementSignificant movement in price has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information ab...
2026-09-16ESOPAllotment of 40500 Shares.
2026-09-01Volume querySignificant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information a...
2026-08-31Volume querySignificant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information a...
2026-08-18Shareholder meetingProceedings of AGM, Voting result and Scrutinisers report.
2026-08-07Investor PresentationInvestor Presentation
2026-08-07Board meeting outcomeKopran Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-16Record DateRecord date for the purpose of Dividend is 11-Aug-2026.
2026-06-26AppointmentAppointment of Mr. Vijay L Thange as Chief Technical Officer of the company w.e.f. Jun 26, 2026.
2026-06-04Shareholder meetingOutcome of the Meeting of the Equity Shareholders, Secured Creditors and Unsecured Creditors convened on Wednesday June 03, 2026
2026-05-20Investor PresentationInvestor Presentation
2026-05-19Board meeting outcomeKopran Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-18Issue of SecuritiesIssue of Securities in its subsidiary company
2026-05-18AppointmentAppointment of as Non- Executive Independent Director in its Subsidiary company w.e.f. May 18, 2026.
2026-05-07Shareholder meetingShareholders meeting
2026-04-30Shareholder meetingNotice of Court Convened General Meeting to be held on Jun 03, 2026
2026-04-30Amalgamation/MergerAmalgamation/Merger
2026-04-10Disclosure under SEBI TakeovKopran Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac...
2026-04-10Disclosure under SEBI TakeovKopran Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac...
2026-04-10Amalgamation/MergerAmalgamation/Merger
2026-04-10Price movementSignificant movement in price has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information ab...
2026-04-09Price movementSignificant movement in price has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information ab...
2026-04-08Volume querySignificant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information a...
2026-04-07Volume querySignificant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information a...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)Short Term Additional Surveillance Measure (Short Term ASM): stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03